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The presence of tumour-associated lymphocytes
confers a good prognosis in pancreatic ductal
adenocarcinoma: an immunohistochemical study
of tissue microarrays
Nilanjana Tewari1, Abed M Zaitoun2, Arvind Arora3,4, Srinivasan Madhusudan3,4, Mohammad Ilyas2,5
and Dileep N Lobo1*
Abstract
Background: Tumour-associated lymphocytes (TALs) have been linked with good prognosis in several solid
tumours. This study aimed to evaluate the prognostic significance of CD3, CD8 and CD20 positive lymphocytes in
pancreatic ductal adenocarcinoma.
Methods: After histological re-evaluation of the tumours of 81 patients who underwent surgical resection for
exclusively pancreatic ductal adenocarcinoma, tissue micro-arrays (TMA) were constructed and
immunohistochemistry was performed for CD3, CD8 and CD20. The number of lymphocytes within specific tumour
compartments (i.e. stromal and intratumoural) was quantified. X-tile software (Yale School of Medicine, CT, USA) was
used to stratify patients into ‘high’ and ‘low’ for each of the lymphocytes stained and their association with survival.
Receiver operating curves (ROC) were constructed to evaluate the association between the TALs, alone and in
combination, with clinicopathological features.
Results: CD3 and CD8 positive lymphocytes were associated with grade of tumour differentiation. The presence of
intratumoural CD3 positive cells was associated with improved survival (p = 0.028), and intratumoural and stromal
CD3 in combination also correlated with improved survival (p = 0.043). When CD20 positive lymphocyte levels were
high, survival improved (p = 0.029) and similar results were seen for CD20 in combination with intratumoural CD3
(p = 0.001) and stromal CD8 (p = 0.013).
Conclusions: This study has shown a correlation between the presence of TALs and survival in pancreatic ductal
adenocarcinoma.
Keywords: CD3, CD8, Pancreatic ductal adenocarcinoma, Tumour-associated lymphocytes, Prognosis,
Immunohistochemistry
Background
Pancreatic cancer is one of the most aggressive of
gastrointestinal malignancies, with a 5- year survival rate
of 4-5% [1,2]. Surgical resection offers the only potential
for cure, but no more than 20% of pancreatic carcin-
omas are resectable [2]. Chemotherapy may be offered
for unresectable disease, but in patients with locally ad-
vanced or metastatic disease, progression-free survival
time after chemotherapy is usually less than 3 months
[3]. Despite advances in surgical technique and reduc-
tion in postoperative mortality, the death rate for pan-
creatic cancer has remained relatively stable [4].
It has long been recognised that the tumour micro-
environment has an important role in the biological be-
haviour of cancer [5]. The host response to presence of
tumour cells can be represented by the presence of
tumour infiltrating immune cells. This reaction has been
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evaluated in a number of solid tumours and several
tumour associated lymphocytes (TALs) have been stu-
died [5-8].
The CD3 antigen is a 20 kD glycoprotein, present on
the surface of all human T lymphocytes [9]. CD8 is a
two chain glycoprotein which is expressed on the surface
of circulating T lymphocytes. CD3 is a generic T-cell re-
ceptor and will identify all T-cells while CD8 is a marker
for cytotoxic T-cells and suppressor T cells [10]. In the
first paper to analyse the profile of tumour infiltrating
lymphocytes [11], CD3, CD8 and some other markers
were evaluated and it was found that both CD3 and
CD8 were associated with prognosis. Staining for CD3
and CD8 has been used in non-small cell lung cancer
[12], colorectal cancer [11] and cutaneous lymphoma
[13] to demonstrate the prognostic significance of TALs.
Many other studies have used a similar strategy and in a
recent meta-analysis of the role of TALs [14], it was con-
cluded that CD3 and CD8 were associated with good
prognosis.
CD20 is a 33-37 kDa transmembrane phosphoprotein
which is expressed on B lymphocyte precursors and ma-
ture B lymphocytes [15,16]. CD20 positive B cell infiltra-
tion has been associated with improved patient survival
in primary breast cancer [16], non-small cell lung cancer
[17] and epithelial ovarian cancer [18]. They have not
previously been studied in cancers of the pancreas. This
study evaluated the prognostic significance of CD3, CD8
and CD20 positive lymphocytes in pancreatic ductal
adenocarcinoma.
Methods
Clinical samples
Patients who underwent surgery with curative intent for
pancreatic ductal adenocarcinoma between 8/3/96 and
21/6/11 were included in this study. All operations
were performed in the Department of Hepatopancrea-
ticobiliary Surgery, Nottingham University Hospitals
NHS Trust. In this centre, 30-50 patients are operated
on per year for periampullary cancer. In this study,
we included only pancreatic ductal adenocarcinomas.
Therefore, tumours of the ampulla, neuroendocrine
tumours, cholangiocarcinomas and any other histo-
logical tumour types were excluded. Types of operations
performed were Whipple’s procedure, total pancreatec-
tomy, and distal pancreatectomy for tumours in the body,
head, neck and tail of pancreas. Median follow up time
was 42 months (6 to 163 months). Ethical approval was
obtained from the National Regional Ethics Service
Committee East Midlands - Nottingham 1 for the use
of anonymised archival specimens and the require-
ment for patient/relative consent was waived by the
Ethics Committee. The study was conducted according to
REMARK criteria [19].
Tissue microarray and immunohistochemistry
Tissue microarrays (TMA) were prepared using tripli-
cate 0.6 mm tissue cores of tumour, identified by a spe-
cialist pathologist (AMZ), placed into a single recipient
paraffin block, using a semi-automated instrument and
Table 1 Cut-offs for tumour associated lymphocytes and
survival from X-tile
Tumour associated lymphocytes Cut-off score (cells/mm2)
Intratumoural CD3 28.3
Stromal CD3 132.0
Intratumoural CD8 11.8
Stromal CD8 48.4
CD20 84.6
Table 2 Clinicopathological data
Sex
Males 54 (66.7%)
Females 27 (33.3%)
Location of tumour
Neck 1 (1.2%)
Body 4 (4.9%)
Tail 9 (11.1%)
Head 67 (82.7%)
Resection Type
Total pancreatectomy 5 (6.2%)
Distal pancreatectomy/extended distal pancreatectomy
and splenectomy
10 (12.3%)
Whipples’ procedure 66 (81.5%)
pT category
pT2 16 (19.8%)
pT3 63 (77.8%)
pT4 2 (2.5%)
pN category
pN0 24 (29.6%)
pN1 57 (70.4%)
Tumour grade (G1 =well, G2 =moderately,
G3 = poorly differentiated)
G1 8 (9.9%)
G2 45 (55.6%)
G3 28 (34.6%)
CD3+ density [Mean (SEM), cells/mm2]
Intratumoural 42.4 (6.60)
Stromal 202.9 (25.9)
CD8+ density [Mean (SEM), cells/mm2]
Intratumoural 15.2 (3.3)
Stromal 36.7 (3.7)
Stromal CD20 density [Mean (SEM), cells/mm2] 27.0 (5.2)
SEM = standard error of the mean.
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targeted cores. Sections of TMA 4 μm thick were moun-
ted on poly-L-lysine coated slides.
Investigation of CD3, CD8 and CD20 was conducted
using a tissue microarray. Immunohistochemical staining
was performed using Bond Max automated staining ma-
chines (Leica Microsystems, Wetzlar, Germany). In our
laboratory the antigen retrieval step is performed on our
automated staining machines. The temperature at which
the Leica Bond Max automated stainers retrieve is 100°C
for the appropriate time (i.e.20 minutes) followed by
12 minutes at ambient temperature. CD3 (NCL-L-CD3-
565, Leica Microsystems) was stained optimally at a di-
lution of 1/100 with antigen retrieval performed using
Epitope Retrieval solution 2 (ER2) for 20 minutes. CD8
(NCL-L-CD8-295, Leica Microsystems) was stained op-
timally at a dilution of 1/50 with antigen retrieval
performed using Epitope Retrieval solution 1 (ER1) for
30 minutes. CD20 (M0755, Dako) was stained optimally
at a dilution of 1/400 with antigen retrieval performed
using ER1 for 20 minutes. ER1 (AR9961, Leica Micro-
systems) is a ready-to-use citrate based pH 6.0 solution;
ER2 (AR9640, Leica Microsystems) is a ready-to-use
EDTA based pH 9.0 solution. Sections were cut, dried
at room temperature for 20 minutes, then incubated at
60°C for 20 minutes prior to loading onto the Bond
stainers (Leica Biosystems, Milton Keynes, UK). The
Bond staining protocol comprises several steps. The first
step is dewaxing using Leica Dewax solution (AR9222)
for 30 seconds at 72°C, followed by the antigen retrieval
step and application of the endogenous peroxidase block
for 5 minutes at room temperature (RT). There follows
primary antibody incubation for 15 minutes at RT, post
primary incubation for 8 minutes at RT, polymer incuba-
tion for 8 minutes at RT, DAB for 10 minutes at RT,
DAB enhancer (AR9432) for 5 minutes at RT and
haematoxylin counterstain for 5 minutes at RT. Wash
steps were performed using Leica Bond Wash solution
(AR9590) between each step. Peroxidase blocks, post
primary, polymer, DAB and Haematoxylin were all sup-
plied in Leica Bond Refine Detection kit (DS9800).
Sections were then removed from the Bond staining ma-
chine, dehydrated in IMS (Genta Medical, Rudgate, UK),
cleared in Xylene (Genta Medical) and permanently
mounted under glass coverslips using Pertex Histolab
(Algol Diagnostics, Espoo, Finland). The sections are
washed in Leica Bond wash buffer to rehydrate after the
dewaxing step.
Evaluation of the number of CD3 and CD8 positive
lymphocytes was performed as follows: the absolute
number of each immunohistochemically detectable
Figure 1 Expression of CD3 in pancreatic ductal adenocarcinoma. Representative photomicrographs of CD3 stained lymphocytes in
pancreatic ductal adenocarcinoma. a: Small number of CD3 lymphocytes in both tumour epithelium (red arrow head) and stroma.
b: Small number of CD3 lymphocytes in tumour epithelium and moderate number of CD3 lymphocytes in stroma (red arrow head) of well
differentiated papillary adenocarcinoma of the pancreas (G1). c: Moderate number of CD3 lymphocytes in tumour epithelium (red arrow head)
and occasional lymphocytes in stroma (green arrow head) of moderately differentiated adenocarcinoma (G2 ). d: Occasional CD3 lymphocytes in
tumour epithelium and small number of CD3 lymphocytes in stroma (red arrow head) red of poorly differentiated papillary adenocarcinoma (G3).
Photomicrographs are at 5× magnification.
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T-cell subgroup was counted manually by two inde-
pendent researchers, one a pathologist. The localisation
of each cell was taken into account – T lymphocytes
lying among epithelial carcinoma cells were regarded as
‘intratumoural’ while those within the tumour stroma
were regarded as ‘stromal’. The proportion of tumour
and stroma was estimated visually by both researchers
independently. From these figures, the densities of lym-
phocytes per mm2 were calculated using the TMA core
area as reference [20]. The mean area of TMA cores
was 0.355 mm2. All cases were scored without prior
knowledge of pathological stage of tumour or patient
outcome.
As CD20 staining was primarily seen in the stroma,
only stromal B lymphocytes stained with CD20 were
counted. The proportion of stroma was estimated by
both researchers independently. These figures were used
to calculate the density of CD20 positive B lymphocytes
in the stroma using the TMA core area as reference.
Therefore, CD20 results are not presented as ‘intratu-
moural’ or ‘stromal’ but simply as ‘CD20’ which refers to
CD20 positive TALs seen in stromal tissue.
Statistical analysis
For inter-observer concordance, a subset of stained cores
was scored by both observers and Kappa statistics were
calculated to assess inter-observer variability. A subset
of complete sections from patients in whom TMA sec-
tions had been evaluated was also scored by both ob-
servers. The mean number of TALs for each group
resulting from the three tumour-TMA cores was at-
tributed to the corresponding patient. The relationship
between categorised protein expression and clinicopath-
ological variables was assessed using Pearson Chi Square
(χ2) test of association. Survival curves were plotted
according to the Kaplan-Meier method and significance
determined using the log-rank test. Multivariate survival
analysis was performed by Cox Proportional Hazards re-
gression model. All differences were deemed statistically
significant at the level of p < 0.05. Statistical analysis was
performed using SPSS 19.0 software (IBM Corporation,
NY, USA).
X-tile software (Yale School of Medicine, CT, USA)
was used to stratify patients into ‘high’ and ‘low’ for each
of the lymphocytes stained. The use of X-tile has been
Figure 2 Expression of CD8 in pancreatic ductal adenocarcinoma. Representative photomicrographs of CD8 stained lymphocytes in
pancreatic ductal adenocarcinoma. a: Occasional CD8 lymphocytes in tumour and stroma in moderately differentiated pancreatic
adenocarcinoma (G2). b: Small number of CD8 lymphocytes in tumour epithelium (red arrow head) and stroma (green arrow head) of
moderately differentiated pancreatic adenocarcinoma (G2). c: Occasional number of CD8 lymphocytes in tumour epithelium and moderate
number in stroma (red arrow head) of papillary (well differentiated) pancreatic adenocarcinoma (G1). d: Small number of CD8 lymphocytes in
tumour (red arrow head) and moderate number in stroma (green arrow head) of poorly differentiated pancreatic adenocarcinoma (G3).
Photomicrographs are at 5× magnification.
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described previously [21]. X-tile plots provide a single,
global assessment of every possible way of dividing a
population into low, medium, and high-level marker ex-
pression. X-tile data are presented in a triangular grid
where each point represents a different cut-point. The
intensity of the colour of each cut-off point represents
the strength of the association. The X-tile software al-
lows the user to move a cursor across the grid and
provides a histogram of the resulting population sub-
sets along with an associated Kaplan-Meier curve.
This histogram can be used to determine the optimal
cut-off point which shows up as the brightest pixel
on the X-tile plot. The use of X-tile software allows
results to be produced on a ‘test’ cohort and tested
on a ‘validation’ cohort. Therefore, all survival results
have been tested in a simulated independent cohort
and found to be valid.
Stratification cut-points were determined using X-Tile
software for survival analysis (Table 1) and receiver op-
erating curves (ROC) for clinicopathological features
and were determined prior to statistical analyses [21].
Results
The study included 81 patients with pancreatic ductal
adenocarcinoma. The median age of the patients was
65 years (range 25-82). The kappa statistic for inter-
observer concordance was 0.78. On comparison of re-
sults of scoring whole tumour sections with TMA cores,
there was no significant difference in mean score for
intratumoural CD3 (p = 0.873), stromal CD3 (p = 0.895),
intratumoural CD8 (p = 0.650), stromal CD8 (p = 0.436)
or CD20 (p = 0.737). Clinicopathological data includ-
ing tumour grade of differentiation are summarised in
Table 2. Of note, there were no specimens in which
lymph node status was pN2 so this is not mentioned
in Table 2.
CD20, CD8 and CD3 expression in pancreatic tumours
CD3 staining was seen in both the tumour tissue and
stroma of pancreatic adenocarcinomas (Figure 1a-d) and
each was scored separately. Similarly, CD8 staining was
seen in tumour and stroma (Figure 2a-d) and each was
scored separately. CD20 staining was seen primarily in
Figure 3 Expression of CD20 in pancreatic ductal
adenocarcinoma. Representative photomicrographs of CD20
expression. a: moderate number of B lymphocytes in the stroma
(red arrow head) in pancreatic carcinoma. b: Lymphoid follicle (red
arrow head) rich in CD20 lymphocytes from patient with pancreatic
carcinoma. c: absence of CD20 in both epithelial component (red
arrow head) and stroma (green arrow head) in poorly differentiated
pancreatic adenocarcinoma (G3). Photomicrographs are at
5× magnification.
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the stroma (Figure 3a). Staining was also seen in lymph-
oid follicles (Figure 3b). In poorly differentiated pancre-
atic adenocarcinomas, there was little positive CD20
staining in either the tumour or stroma (Figure 3c).
Survival analysis
There was no association between sex of patients and
survival (p = 0.113) (Figure 4a). There was also no sig-
nificant association between tumour grade and survival
(p = 0.103) (Figure 4b). Kaplan Meier plots of survival
in pancreatic ductal adenocarcinoma in the presence
of TALs alone, or in combination, are shown in
Figure 5 (a-d) and Figure 6 (a-d). The presence of
intratumoural CD3 correlated with improved survival
(p = 0.028). When intratumoural CD3 and stromal
CD3 were present, survival was improved (p = 0.043).
The presence of CD20 positive lymphocytes correlated
with improved survival (p = 0.029). When intratumou-
ral CD3 and CD20 were present and stromal CD8
and CD20 were present, survival appeared improved
(p = 0.001 and p = 0.013 respectively).
Regression analyses
Cut-offs values for each of the clinicopathological fea-
tures were determined using ROC curves. A number of
prognostic factors including presence of venous inva-
sion, perineural invasion, tumour size, grade of differen-
tiation and lymph node status (positive or negative for
tumour) were tested to determine whether CD3, CD8
and CD20 positive lymphocytes in the tumour or stroma
were related to them.
In pancreatic ductal adenocarcinoma, the presence of
intratumoural CD3 was significantly associated with
grade of tumour differentiation (p = 0.049). Stromal CD8
also correlated with grade of tumour differentiation
(p = 0.015). The presence of stromal CD3 and CD8 in
combination, and stromal and intratumoural CD3 in
combination also correlated with grade of tumour dif-
ferentiation (p = 0.049 and p = 0.010 respectively). The
only other positive correlation was between the pres-
ence of intratumoural CD8 and CD20 in combination
with perineural invasion (p = 0.048). Table 3 shows all
the correlations tested with their results.
Discussion
In this study we have evaluated the prognostic signifi-
cance of TALs in pancreatic ductal adenocarcinomas.
This cancer generally presents at an advanced stage and
is associated with poor prognosis. In cancer patients, the
identification of markers which could predict survival or
risk of metastases would be useful [22]. The finding of a
correlation between the presence of CD3 positive lympho-
cytes in the tumour tissue and improved survival in pan-
creatic ductal adenocarcinoma is promising. In addition,
the combination of tumoural CD3 and CD20 as well as
stromal CD8 and CD20 correlated with survival. This
bodes well for the development of potential therapeutic
targets, although it may take a significant length of time.
Although there are a number of indicators of outcome
Figure 4 Association of survival and patient/ tumour
characteristics. Kaplan Meier survival curves showing survival
associated with a: gender - males (n=54) and females (n=27) and
b: grade of tumour differentiation: G1 – well differentiated (n=8), G2 –
moderately differentiated (n=45), G3 – poorly differentiated (n=28).
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available, such as nodal involvement and resection margin,
the addition of further markers such as the presence of
tumour associated lymphocytes may allow us to provide
additional useful information to the patient regarding their
prognosis.
This study demonstrated that the presence of CD3
and CD8 positive lymphocytes was associated with in-
creasing grade of tumour differentiation in pancreatic
ductal adenocarcinoma. Although we did not demon-
strate a significant association between tumour grade
and survival, it is well established that poorly differenti-
ated pancreatic cancers are associated with poorer sur-
vival [23]. Our results suggest that well differentiated
tumours may be associated with a more aggressive im-
mune reaction and, therefore, confer a more favourable
prognosis.
There was also an association between the presence of
high levels of CD20 in combination with intratumoural
CD8 and perineural invasion. Perineural invasion in
pancreatic cancer is associated with poor prognosis
Figure 5 Association of survival and tumour associated lymphocytes. Kaplan Meier survival curves comparing patients with pancreatic
ductal adenocarcinoma a: where intratumoural CD3 was high (N=33) vs. low (N=48) b: where stromal CD3 was high (N=40) vs. low (N=41)
c: where stromal CD8 was high (N=18) vs. low (N=63) d: where CD20 was high (N=36) vs. low (N=45).
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[24,25] and may be present even in the absence of
lymph node metastases [26]. It is difficult to explain
the finding that the presence of CD8 and CD20 posi-
tive lymphocytes correlated with other known poor
prognostic markers, such as perineural invasion but
also correlated with improved survival. In other solid
tumours, such as thyroid cancer, the presence of TALs
has been associated with more aggressive disease [27].
However, in colorectal cancer, the presence of TALs sig-
nifies an inflammatory cell reaction at the tumour inva-
sive border and appears to be a useful predictor of
survival [28].
This study also evaluated CD20, a marker for B lym-
phocytes, in pancreatic cancer. CD20 positive B lympho-
cytes have been recently evaluated in advanced gastric
cancer [29] and were found not to be associated with
Figure 6 Association of survival and tumour associated lymphocytes. Kaplan Meier survival curves comparing patients with pancreatic
ductal adenocarcinoma a: where intratumoural CD3 and stromal CD3 were high (N=22) vs. low (N=59) b: stromal CD3 and CD20 were high
(N=14) vs. low (N=67) c: stromal CD8 and CD20 were high (N=13) vs. low(N=68) d: where stromal and intratumoural CD3, stromal and
intratumoural CD8 and CD20 were all high (N=5) vs. low (N=76).
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prognosis in prostate cancer [30]. The novel finding of a
positive association between CD20 positive B lympho-
cytes and survival in pancreatic ductal adenocarcinoma
merits further investigation.
Conclusions
In summary, our study evaluated the presence of CD3,
CD8 and CD20 positive lymphocytes in a large series of
surgically resected pancreatic ductal adenocarcinoma
and demonstrated correlation with survival in pancreatic
cancer, which may be related to lymph node metastases,
perineural invasion or tumour size. One of the limita-
tions of this study is the use of TMAs which may not be
representative of the whole tumour specimen because of
tissue heterogeneity. However, the use of TMA cores
constructed in triplicate has been shown to provide a
sufficient level of sampling uniformity [31,32]. Al-
though archival specimens were used, previous studies
have suggested that many proteins are antigenically
retrievable on tissues stored for more than 60 years
[33]. In conclusion, this study of TALs has shown
that they are associated with improved survival in
pancreatic ductal adenocarcinoma. The surprising fin-
ding of a positive association between CD20, intra-
tumoural CD8 and perineural invasion was also reported.
Whether this has a bearing on survival is not clear
from our results. Future studies are needed to con-
firm these results in an independent data set and to
elucidate the exact mechanisms of a lymphocytic re-
action to tumour.
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